Currenc Group Inc

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October.

CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi-Channel Distribution Platform Company

- CURE will present at the LD 500 Virtual Conference, September 4 at 8:20 am PDT - 

CURE Pharmaceutical to Present at Two Virtual Events in September

SHERMAN OAKS, Calif.--(BUSINESS WIRE)-- #Beauty--Sera Labs, a Leader in the CBD Industry to be acquired by CURE Pharmaceutical in a $20 Million Transaction

Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, to be acquired by CURE Pharmaceutical in a $20 Million Transaction

Significantly higher serum concentration and absorption Showcases CUREform™ encapsulation and oral thin film technology Significantly higher serum concentration and absorption Showcases CUREform™ encapsulation and oral thin film technology

CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel

OXNARD, Calif., July  08, 2020  (GLOBE NEWSWIRE) -- CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today announced that its 25,000 square foot manufacturing facility has earned NSF International, cGMP certification for the manufacture of dietary supplements. This certification is issued only after extensive material and facility analysis and gives suppliers, retailers, regulators and consumers assurance that products manufactured by CURE meet the highest standards for safety, quality, sustainability and performance.

CURE Pharmaceutical Receives NSF’s cGMP Certification for Dietary Supplements

- Jonathan Berlent Appointed to Newly Created Role - - Jonathan Berlent Appointed to Newly Created Role -

CURE Pharmaceutical Appoints Chief Business Officer

OXNARD, Calif., June  09, 2020  (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR), an innovative drug delivery company that is developing novel ways to deliver active ingredients, announced today that it strengthened its balance sheet with the receipt of $1.4 million in cash from the exercise of warrants to purchase 708,467 shares of CURE’s common stock held by certain stockholders of Chemistry Holdings, Inc. (Chemistry Holdings) at a reduced exercise price of $2.00 per share (which was 10 percent above the market price for CURE’s stock at closing).  The warrant exercise is part of the completion of all earn-out arrangements and obligations related to CURE’s acquisition of Chemistry Holdings on May 14, 2019.

CURE Pharmaceutical Announces Exercise of Warrants for Cash Proceeds of Approximately $1.4 Million and Completes Earn Out Related to 2019 Acquisition

News for Currenc Group Inc Stock (CURR)